CN110709413B - 人白细胞介素27α-亚基的能够分泌的突变蛋白 - Google Patents

人白细胞介素27α-亚基的能够分泌的突变蛋白 Download PDF

Info

Publication number
CN110709413B
CN110709413B CN201880029727.9A CN201880029727A CN110709413B CN 110709413 B CN110709413 B CN 110709413B CN 201880029727 A CN201880029727 A CN 201880029727A CN 110709413 B CN110709413 B CN 110709413B
Authority
CN
China
Prior art keywords
alpha
mutein
subunit
seq
human interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880029727.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN110709413A (zh
Inventor
M·菲戈
S·穆勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technische Universitaet Muenchen
Original Assignee
Technische Universitaet Muenchen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technische Universitaet Muenchen filed Critical Technische Universitaet Muenchen
Publication of CN110709413A publication Critical patent/CN110709413A/zh
Application granted granted Critical
Publication of CN110709413B publication Critical patent/CN110709413B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880029727.9A 2017-05-04 2018-05-04 人白细胞介素27α-亚基的能够分泌的突变蛋白 Active CN110709413B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17169358.3 2017-05-04
EP17169358 2017-05-04
PCT/EP2018/061561 WO2018202876A1 (en) 2017-05-04 2018-05-04 Secretion-competent muteins of the human il-27 alpha-subunit

Publications (2)

Publication Number Publication Date
CN110709413A CN110709413A (zh) 2020-01-17
CN110709413B true CN110709413B (zh) 2023-11-28

Family

ID=58669684

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880029727.9A Active CN110709413B (zh) 2017-05-04 2018-05-04 人白细胞介素27α-亚基的能够分泌的突变蛋白

Country Status (7)

Country Link
US (1) US11358998B2 (https=)
EP (1) EP3619228A1 (https=)
JP (1) JP7249955B2 (https=)
CN (1) CN110709413B (https=)
AU (1) AU2018262811B2 (https=)
CA (1) CA3060219A1 (https=)
WO (1) WO2018202876A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7641912B2 (ja) 2019-04-19 2025-03-07 シナーキン・ファーマ・ベスローテン・フエンノートシャップ Ｉｌ１３を含む融合タンパク質
US20220380426A1 (en) * 2019-11-12 2022-12-01 Technische Universitat Mu Homogeneous muteins of the human il-27 alpha-subunit
CN113307861A (zh) * 2020-12-09 2021-08-27 重庆医科大学 细胞因子il-27作为nec与fpies鉴别诊断标志物及应用
WO2024213695A1 (en) * 2023-04-14 2024-10-17 Technische Universitaet Muenchen Method for producing the subunits of human interleukin 35 from interleukin 12 and interleukin 27
CN116832146B (zh) * 2023-06-30 2024-02-13 广东暨安特博生物科技有限公司 Il-27蛋白在制备治疗阿尔茨海默症的产品的应用
WO2025140436A1 (zh) * 2023-12-27 2025-07-03 上海药明生物技术有限公司 重组il-27蛋白及其制备方法
WO2025252853A1 (en) * 2024-06-04 2025-12-11 Technische Universitaet Muenchen, In Vertretung Des Freistaates Bayern Fusion-polypeptide comprising a mutein of the alpha-subunit of human il-27 and at least one pharmaceutically acceptable fusion partner

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1973898A (zh) * 2005-03-14 2007-06-06 复旦大学 一种含p28分子或其基因的医药制剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2831100A4 (en) * 2012-03-26 2016-02-10 Pronutria Inc NUTRIENT PROTEINS AND METHOD

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1973898A (zh) * 2005-03-14 2007-06-06 复旦大学 一种含p28分子或其基因的医药制剂

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A role for IL-27p28 as an antagonist of gp130-mediated signaling;Jason S. Stumhofer 等;《Nature Immunology》;20101107;第11卷(第12期);摘要，第1120页左栏最后1段-右栏第1段，第1125页左栏第4段，图1 *
IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells;Stefan Pflanz 等;《Immunity》;20020630;第16卷(第6期);摘要，第780页右栏第1段-第781页右栏第1段，第786页左栏第2段-右栏第1段，图1-2 *
The secreted form of p28 subunit of interleukin (IL)-27 inhibits biological functions of IL-27 and suppresses anti-allogeneic immune responses;Osamu Shimozato 等;《Immunology》;20091231;第128卷;摘要，第e818页右栏最后1段-第e819页左栏第1段，第e823页左栏第1段，图1 *

Also Published As

Publication number Publication date
JP2020518249A (ja) 2020-06-25
JP7249955B2 (ja) 2023-03-31
AU2018262811B2 (en) 2021-10-21
WO2018202876A1 (en) 2018-11-08
EP3619228A1 (en) 2020-03-11
US20200062817A1 (en) 2020-02-27
AU2018262811A1 (en) 2019-12-19
US11358998B2 (en) 2022-06-14
CA3060219A1 (en) 2018-11-08
CN110709413A (zh) 2020-01-17

Similar Documents

Publication Publication Date Title
CN110709413B (zh) 人白细胞介素27α-亚基的能够分泌的突变蛋白
JP6884708B2 (ja) Ｃｄ１３７に特異的なタンパク質
EP2035452B1 (en) Soluble heterodimeric receptors and uses thereof
US11462297B2 (en) Selective peptide antagonists
Guo et al. Protection against Th17 cells differentiation by an interleukin-23 receptor cytokine-binding homology region
Swee et al. Biological activity of ectodysplasin A is conditioned by its collagen and heparan sulfate proteoglycan-binding domains
Kuchař et al. Human interleukin‐23 receptor antagonists derived from an albumin‐binding domain scaffold inhibit IL‐23‐dependent ex vivo expansion of IL‐17‐producing T‐cells
KR20180029238A (ko) Lag-3에 특이적인 신규 단백질
Müller et al. An interspecies analysis reveals molecular construction principles of interleukin 27
Goodrich et al. Production of calcium-mobilizing metabolites by a novel member of the ADP-ribosyl cyclase family expressed in Schistosoma mansoni
WO2018087108A1 (en) Proteins specific for cd137
US20230192793A1 (en) Il-37 fusion proteins and uses thereof
Qian et al. Construction of a plasmid for co-expression of mouse membrane-bound form of IL-15 and RAE-1ε and its biological activity
CN115038717A (zh) 人IL-27α-亚基的同质突变蛋白
Huang et al. A novel strategy to produce high level and high purity of bioactive IL15 fusion proteins from mammalian cells
Tomida Presence of mRNAs encoding the soluble D-factor/LIF receptor in human choriocarcinoma cells and production of the soluble receptor
EP4695283A1 (en) Method for producing the subunits of human interleukin 35 from interleukin 12 and interleukin 27
US6258943B1 (en) Human neurokinin-3 receptor
Müller Folding and quality control of the interleukin 12 family cytokines interleukin 27 and interleukin 35
Shen et al. Molecular structure, bioinformatics analysis, expression and bioactivity of BAFF (TNF13B) in dog (Canis familiaris)
WO2025252853A1 (en) Fusion-polypeptide comprising a mutein of the alpha-subunit of human il-27 and at least one pharmaceutically acceptable fusion partner
Mazzone et al. Functional Characterization of Porcine (Sus scrofa) BCL10
Martínez de Arbulo Echevarría et al. A Stretch of Negatively Charged Amino Acids of Linker for Activation of T-Cell Adaptor Has a Dual Role in T-Cell Antigen Receptor Intracellular Signaling
INTERNALIZATION CXCR1 and CXCR2 Activation and Regulation
JP2001103974A (ja) タンパク質Ｒｉｍ２

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant